No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ACAD ACADIA Pharmaceuticals
- 16.810
- -0.260-1.52%
Trading Apr 19 15:54 ET
2.77BMarket Cap-45432P/E (TTM)
17.295High16.620Low1.21MVolume16.980Open17.070Pre Close20.30MTurnover1.10%Turnover RatioLossP/E (Static)164.77MShares33.99052wk High6.42P/B1.85BFloat Cap16.60052wk Low--Dividend TTM109.87MShs Float58.720Historical High--Div YieldTTM3.95%Amplitude0.650Historical Low16.802Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | ACADIA Pharmaceuticals Inc : Needham Cuts Target Price to $30 From $32: Needham Cuts Target Price to $30 From $32
Acadia Pharmaceuticals Presents New DAYBUE Clinical Data At The 2024 American Academy Of Neurology Annual Meeting
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that two oral presentations featuring DAYBUE (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (A
Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
26 analysts have expressed a variety of opinions on ACADIA Pharmaceuticals (NASDAQ:ACAD) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table provides
Express News | Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $37 Price Target
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
Taysha Draws Bullish View at Piper Sandler on Lead Asset
Comments
Analysts have high confidence in ACADIA Pharmaceuticals, predicting an average annual growth rate of 42%. The company's lack of debt reduces concerns around repayments and makes it a less risky investment.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) On The Verge Of Breaking Even 1
Several companies were in the spotlight due to various developments:
Oracle ( $Oracle(ORCL.US$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $ACADIA Pharmaceuticals(ACAD.US$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts(MTN.US$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$Asana(ASAN.US$ Asana rep...
Oracle ( $Oracle(ORCL.US$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $ACADIA Pharmaceuticals(ACAD.US$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts(MTN.US$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$Asana(ASAN.US$ Asana rep...
2
$ACADIA Pharmaceuticals(ACAD.US$ And where will the bottom be? Could it be a opportunity? Time will tell? Hehehe
Ouch! I’m seeing a drop coming?
$ACADIA Pharmaceuticals(ACAD.US$ Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effe...
1
6
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg